Author:
Nass Sharyl J.,Rothenberg Mace L.,Pentz Rebecca,Hricak Hedvig,Abernethy Amy,Anderson Kenneth,Gee Amanda Wagner,Harvey R. Donald,Piantadosi Steven,Bertagnolli Monica M.,Schrag Deborah,Schilsky Richard L.
Publisher
Springer Science and Business Media LLC
Reference94 articles.
1. Gan, H. K., You, B., Pond, G. R. & Chen, E. X. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J. Natl Cancer Inst. 104, 590–598 (2012).
2. Hwang, T. J. et al. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern. Med. 176, 1826–1833 (2016).
3. American Association for Cancer Research. AACR cancer progress report 2011. Roswell Park
https://www.roswellpark.org/sites/default/files/node-files/asset/nid91575-2011-aacr-cpr-text-web.pdf
(2011).
4. Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics
https://doi.org/10.1093/biostatistics/kxx069
(2018).
5. Dagher, R. et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8, 3034 (2002).
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献